Loading Page
Dr. Jimmitti Teysir, MD is a medical oncologist in New York, NY specializing in medical oncology and adult oncology. She graduated from Mount Sinai School of Medicine. Dr. Jimmitti Teysir, MD is affiliated with Memorial Sloan Kettering Cancer Center.
Dr. Jimmitti Teysir, MD graduated from Mount Sinai School of Medicine. She completed residency at Massachusetts General Hospital. She is certified by the Board Certification: Internal Medicine and has a state license in New York.
Medical School: Mount Sinai School of Medicine
Residency: Massachusetts General Hospital
Board Certification: Board Certification: Internal Medicine
Licensed In: New York
Dr. Jimmitti Teysir, MD appears to accept the following insurance providers: Horizon Blue Cross Blue Shield New Jersey (PPO), Magnacare, Emblem, Oscar, Fidelis Medicare Advantage, Emblem Medicare Advantage, Healthsmart, Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan), Aetna, Tricare, Oxford, Straight NY Medicaid, Healthfirst, Cigna, Qualcare, MVP, Connecticare, Healthfirst Medicare Advantage, First Health, Multiplan/Beech Street/PHCS, World Trade Center Health Program (WTC), Blue Cross Blue Shield states outside of NY/NJ, Empire Essential, Non-Participating Plans with Out of Network Benefits, Blue Cross Blue Shield New York, Blue Cross Blue Shield Federal Employee Program, UMR, Medicare Part A&B (traditional Medicare), Carrum Health and Blue Cross Health Plus.
According to our sources, Dr. Jimmitti Teysir, MD accepts the following insurance providers:
Dr. Jimmitti Teysir, MD has an exceptional overall rating with an average of 4.92 out of 5 stars based on 201 ratings. We collect ratings and reviews of Dr. Jimmitti Teysir, MD from all over the web to help you find the right in New York, NY.
I am a breast medical oncologist at Memorial Sloan Kettering Cancer Center (MSK), who diagnoses and treats people for breast cancer. I see patients at the Evelyn H. Lauder Breast Center in New York City. My research focuses on clinical trials related to hormone receptor–positive breast cancer, with an emphasis on understanding and overcoming treatment resistance.
